Alioth Completes Over RMB 100 Million Pre-B Round Financing, Establishing a New Benchmark for Domestic Biopharmaceutical Filtration with Proprietary Membrane Material Technology

2

Founder's Statement

Jia Qijun, Founder and Chairman of Alioth, expressed gratitude to SDIC Unity Capital, Hony Capital, Efung Capital, and Guoshun Investment for their trust and support. "This recognition not only validates our unwavering focus on independent innovation, deep exploration of membrane material technology, and service to biopharmaceutical industry clients but also injects strong momentum into our next phase of rapid development. Biopharmaceutical supply chain security has become a vital component of national strategy, and domestic substitution is embracing unprecedented growth opportunities. Alioth will take this as a new starting point, continuously evolving in R&D innovation and advanced manufacturing capabilities, accelerating capacity deployment, and promoting greater autonomy and controllability in core products and technologies while continuously iterating and upgrading. Our goal is not only to serve as the 'cornerstone of security' for China's biopharmaceutical supply chain but also to become a globally innovative partner with technological leadership in the biopharmaceutical process sector. With cutting-edge membrane material technology and high-quality products, we aim to provide global clients with reliable, efficient, and high-value solutions, driving high-quality development in the biopharmaceutical industry."

Investor Statements

SDIC Unity Capital Biopharmaceutical Team: Against the backdrop of China's thriving biopharmaceutical industry, membrane filtration technology, as a key process in the upstream biopharmaceutical sector, faces increasingly prominent supply chain security and autonomy challenges. The domestic market remains dominated by overseas giants like Merck, particularly in mid-to-high-end markets such as virus removal. Alioth boasts a world-class team in membrane material development and application, with original innovation capabilities in core membrane materials. Its filtration products have gained market access and recognition from multiple leading pharmaceutical companies. SDIC Unity Capital will fully leverage its industrial ecosystem resources to support Alioth's continuous independent innovation, accompanying and empowering the company to become a global leader in the membrane filtration field, contributing to China's biopharmaceutical supply chain security and autonomy.

Hony Capital Healthcare Team: The security and global competitiveness of China's biopharmaceutical supply chain rely on strategic support from upstream core materials. Membrane filtration, serving as the dual bastion of "precision" and "security" in biopharmaceutical processes, represents the final frontier in the journey toward autonomous and controllable upstream supply chains. Alioth's value lies not only in its solid original innovations breaking the long-term monopoly of international giants but also in its precise entry at a critical historical juncture—as China's biopharmaceutical industry transitions from "imitation-based innovation" to "source innovation," its supply chain demands have evolved from "cost controllability" to "reliable quality, autonomous supply, and technological co-progression." Hony's confidence in Alioth stems from its team's profound process understanding and sustained deep cultivation in membrane materials, constructing systemic capabilities that transcend single-product substitution and laying a solid supply chain foundation for Chinese pharmaceutical companies competing globally. We look forward to deeply accompanying and empowering the company with capital and industrial ecosystem strength, leveraging Hony's cross-border industrial resources and integration capabilities to help Alioth advance from a domestic benchmark to the global stage, jointly reshaping the competitive landscape of the global filtration market.

Efung Capital Managing Director Fan Rongkui: In the post-pandemic era, compounded by geopolitical factors, domestic substitution has largely broken through in upstream biopharmaceutical sectors such as single-use bioreactors, reaction bags, chromatography equipment, fillers, and culture media, leaving membrane filtration as the final "bottleneck" area. Positioned at the strategic nexus of "supply chain security" and "technological autonomy," membrane filtration has long been monopolized by international giants like Merck, Pall, and Sartorius. As an emerging domestic leader in this sector, Alioth boasts an excellent core team with deep process understanding, and its products have penetrated the supply chains of domestic leading pharmaceutical companies and CXOs. We anticipate Alioth's continued growth, evolving from pursuit to surpassing and standing on the international stage as a key global partner for biopharmaceutical companies.

Guoshun Investment: Biopharmaceutical filtration membranes serve as critical consumables throughout the entire drug research, development, and production lifecycle. The domestic market remains dominated by overseas giants like Merck, Pall, and Sartorius. With the sustained development of the biopharmaceutical industry, supply chain security and autonomy for filtration membranes have become increasingly prominent. As an innovative player in this sector, Alioth's core team possesses extensive R&D capabilities in filtration membranes, with its products entering multiple domestic leading pharmaceutical companies. We expect Alioth to achieve true technological breakthroughs in this "bottleneck" area of biopharmaceutical filtration membranes, continuously innovating and refining to ultimately become a global leader in the membrane filtration field.